» Articles » PMID: 24969085

An Integrated Computational Approach Can Classify VHL Missense Mutations According to Risk of Clear Cell Renal Carcinoma

Overview
Journal Hum Mol Genet
Date 2014 Jun 28
PMID 24969085
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the von Hippel-Lindau (VHL) gene are pathogenic in VHL disease, congenital polycythaemia and clear cell renal carcinoma (ccRCC). pVHL forms a ternary complex with elongin C and elongin B, critical for pVHL stability and function, which interacts with Cullin-2 and RING-box protein 1 to target hypoxia-inducible factor for polyubiquitination and proteasomal degradation. We describe a comprehensive database of missense VHL mutations linked to experimental and clinical data. We use predictions from in silico tools to link the functional effects of missense VHL mutations to phenotype. The risk of ccRCC in VHL disease is linked to the degree of destabilization resulting from missense mutations. An optimized binary classification system (symphony), which integrates predictions from five in silico methods, can predict the risk of ccRCC associated with VHL missense mutations with high sensitivity and specificity. We use symphony to generate predictions for risk of ccRCC for all possible VHL missense mutations and present these predictions, in association with clinical and experimental data, in a publically available, searchable web server.

Citing Articles

Saturation genome editing maps the functional spectrum of pathogenic VHL alleles.

Buckley M, Terwagne C, Ganner A, Cubitt L, Brewer R, Kim D Nat Genet. 2024; 56(7):1446-1455.

PMID: 38969834 PMC: 11250436. DOI: 10.1038/s41588-024-01800-z.


Characterizing and predicting ccRCC-causing missense mutations in Von Hippel-Lindau disease.

Serghini A, Portelli S, Troadec G, Song C, Pan Q, Pires D Hum Mol Genet. 2023; 33(3):224-232.

PMID: 37883464 PMC: 10800015. DOI: 10.1093/hmg/ddad181.


VHL mosaicism: the added value of multi-tissue analysis.

Oldfield L, Grzybowski J, Grenier S, Chao E, Downs G, Farncombe K NPJ Genom Med. 2022; 7(1):21.

PMID: 35304467 PMC: 8933488. DOI: 10.1038/s41525-022-00291-3.


Systematic evaluation of computational tools to predict the effects of mutations on protein stability in the absence of experimental structures.

Pan Q, Nguyen T, Ascher D, Pires D Brief Bioinform. 2022; 23(2).

PMID: 35189634 PMC: 9155634. DOI: 10.1093/bib/bbac025.


von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.

Tedesco L, Elguero B, Gonilski Pacin D, Senin S, Pollak C, Garcia Marchinena P Cell Death Dis. 2019; 10(4):266.

PMID: 30890701 PMC: 6424967. DOI: 10.1038/s41419-019-1507-3.


References
1.
Bond J, Gale D, Connor T, Adams S, de Boer J, Gascoyne D . Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood. 2011; 117(13):3699-701. DOI: 10.1182/blood-2010-12-327569. View

2.
Knauth K, Bex C, Jemth P, Buchberger A . Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Oncogene. 2005; 25(3):370-7. DOI: 10.1038/sj.onc.1209062. View

3.
Sjursen W, Halvorsen H, Hofsli E, Bachke S, Berge A, Engebretsen L . Mutation screening in a Norwegian cohort with pheochromocytoma. Fam Cancer. 2013; 12(3):529-35. DOI: 10.1007/s10689-013-9608-0. View

4.
Nordstrom-OBrien M, van der Luijt R, van Rooijen E, van den Ouweland A, Majoor-Krakauer D, Lolkema M . Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010; 31(5):521-37. DOI: 10.1002/humu.21219. View

5.
Schoenfeld A, Davidowitz E, Burk R . Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci U S A. 2000; 97(15):8507-12. PMC: 26978. DOI: 10.1073/pnas.97.15.8507. View